Health is among the key areas of prime concern among most people. With the advent of the discipline of medicine, health has been improved a great deal. Extensive research has been conducted in the past, and is still an ongoing process, in a bid to curb and eliminate all sorts of health problems. Among the recent breakthroughs is concerned with liposomal formulation.
The process of this formulation was discovered 50 years ago. It came about as a solution to a problem of drugs taken orally being exhausted and digested before reaching the intended target areas. The liposomal way was deemed best suited since it was a favorable carrier to both hydrophilic and hydrophobic drugs.
The simplicity of the liposomes' structural composition is key to its performance. They are made up of an aqueous solution which is engulfed in a strengthened mesh of either natural or synthetic phospholipids. The advantage of this is that it can fuse non-reactively with both hydrophilic and hydrophobic drugs, each attaching to the element it does not react to.
The core structure of liposomes is what causes them to be preferred among researchers of various fields and disciplines. They are formed when phospolipids are immersed in water and a specific amount of heat directed toward them. To determine if it is an appropriate carrier for a given drug, the chemical composition should be bench-marked against that of the drug, so as to avert reactions.
Advances such as these have led to further progress in the medical field. The most famous being development of Doxorubicin, a form of anthracycline. This is a drug that was developed to curb the spread of cancer. It does this in two stages, first, by inserting base stains of DNA and RNA molecules which inhibits replication of cells. The second phase is inhibition of an enzyme known as topoisomerase II, which serves the same purpose of inhibition of cellular growth.
Research and development has been kicked into top gear with the discovery and advancement of this formulation. There are high expectations from various areas on the development of drugs to help the fight against most terminal illnesses. There has been consistent research in developing anti-cancer drugs in the recent past. Drugs such as doxorubicin, paclitaxel, cisplatin, lipoplatin and aroplatin have been developed and testing is ongoing for the same purpose.
Some diseases which were considered deadly can now be mitigated via vaccines. Research in the field of liposomes has led to development of several vaccines which can now be actively used as preventative medicine. Most however are still undergoing rigorous testing. Some of the vaccines created include Inflexal V against influenza, Epaxal for Hepatitis, and Stimuvax for cancer.
The formulation is being investigated on how well it will serve in transportation of dietary supplements to various parts of the body. This testing is inspired by the exceptional success in performance of liposomes in targeted drug delivery. If successful, scientists will use liposomes to transport supplements to various parts of the body where they are required by the body. This procedure has been tried and worked. Therefore, its no longer a risk.
The process of this formulation was discovered 50 years ago. It came about as a solution to a problem of drugs taken orally being exhausted and digested before reaching the intended target areas. The liposomal way was deemed best suited since it was a favorable carrier to both hydrophilic and hydrophobic drugs.
The simplicity of the liposomes' structural composition is key to its performance. They are made up of an aqueous solution which is engulfed in a strengthened mesh of either natural or synthetic phospholipids. The advantage of this is that it can fuse non-reactively with both hydrophilic and hydrophobic drugs, each attaching to the element it does not react to.
The core structure of liposomes is what causes them to be preferred among researchers of various fields and disciplines. They are formed when phospolipids are immersed in water and a specific amount of heat directed toward them. To determine if it is an appropriate carrier for a given drug, the chemical composition should be bench-marked against that of the drug, so as to avert reactions.
Advances such as these have led to further progress in the medical field. The most famous being development of Doxorubicin, a form of anthracycline. This is a drug that was developed to curb the spread of cancer. It does this in two stages, first, by inserting base stains of DNA and RNA molecules which inhibits replication of cells. The second phase is inhibition of an enzyme known as topoisomerase II, which serves the same purpose of inhibition of cellular growth.
Research and development has been kicked into top gear with the discovery and advancement of this formulation. There are high expectations from various areas on the development of drugs to help the fight against most terminal illnesses. There has been consistent research in developing anti-cancer drugs in the recent past. Drugs such as doxorubicin, paclitaxel, cisplatin, lipoplatin and aroplatin have been developed and testing is ongoing for the same purpose.
Some diseases which were considered deadly can now be mitigated via vaccines. Research in the field of liposomes has led to development of several vaccines which can now be actively used as preventative medicine. Most however are still undergoing rigorous testing. Some of the vaccines created include Inflexal V against influenza, Epaxal for Hepatitis, and Stimuvax for cancer.
The formulation is being investigated on how well it will serve in transportation of dietary supplements to various parts of the body. This testing is inspired by the exceptional success in performance of liposomes in targeted drug delivery. If successful, scientists will use liposomes to transport supplements to various parts of the body where they are required by the body. This procedure has been tried and worked. Therefore, its no longer a risk.
About the Author:
You can visit purensm.com for more helpful information about Medical Breakthroughs From Liposomal Formulation.